Potent mitochondria-targeted peptides reduce myocardial infarction in rats.

Cho J, Won K, Wu D, Soong Y, Liu S, Szeto HH, Hong MK

Coronary artery disease1 May 2007Cited by 115 (Europe PMC)

PMID17429296DOI10.1097/01.mca.0000236285.71683.b6PepBankPUB-17429296

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

3 results from studies that gave the peptide. No result from this study comes from people.

01AnimalAnimal study (in vivo)Efficacy outcome
In rats with ischemia-reperfusion, the area at risk was similar among SS‑31, SS-20 and control groups.
In plain wordsIn rats, the heart area at risk was similar in all groups, including the SS‑31 group.
Peptide
Elamipretide (SS-31)
Outcome
No significant changeArea at risk
Study
ratn = 24
Myocardial ischemia-reperfusion by LAD ligation
Comparator
Saline
Outcome group
Myocardial injury · Cardiovascular
Studied dose
3 mg/kg · intraperitoneal · Two doses: 30 min before ligation and 5 min before reperfusionAs given in this study (rat).
Source sentences
Summary
The area at risk was similar among the groups.
2 context sentences(design, population, supporting numbers)
Summary · context
Rats (n=8/group) were randomized to SS-31, SS-20 or placebo.
Summary · context
The drugs (3 mg/kg) or saline was administered intraperitoneally 30 min before ligation of the left anterior descending artery for 60 min, and another dose given intraperitoneally 5 min before reperfusion for 60 min.
Report a problemFND-1742929602
02AnimalAnimal study (in vivo)Efficacy outcome
In rats with ischemia-reperfusion, SS‑31 reduced the infarct area relative to area at risk compared with controls.
In plain wordsIn rats given SS‑31 before a heart attack, the damaged heart area was smaller than in rats given saline.
Peptide
Elamipretide (SS-31)
Outcome
DecreaseInfarct area/area at risk
Study
ratn = 16
Myocardial ischemia-reperfusion by LAD ligation
Comparator
Saline
Outcome group
Myocardial injury · Cardiovascular
Studied dose
3 mg/kg · intraperitoneal · Two doses: 30 min before ligation and 5 min before reperfusionAs given in this study (rat).
Measurements
Infarct area/area at risk
53.9%
SS-31
Infarct area/area at risk
59.9%
Control
Source sentences
Summary
The infarct area/area at risk, however, was significantly smaller in the treatment groups (53.9+/-1.1% in SS-31 group, 47.1+/-1.4% in SS-20 group, versus 59.9+/-1% in the controls, P<0.01).
2 context sentences(design, population, supporting numbers)
Summary · context
Rats (n=8/group) were randomized to SS-31, SS-20 or placebo.
Summary · context
The drugs (3 mg/kg) or saline was administered intraperitoneally 30 min before ligation of the left anterior descending artery for 60 min, and another dose given intraperitoneally 5 min before reperfusion for 60 min.
Report a problemFND-1742929601
03AnimalAnimal study (in vivo)Mechanism
In rats with ischemia-reperfusion, SS‑31 significantly reduced myocardial lipid peroxidation.
In plain wordsIn rats given SS‑31 before a heart attack, heart tissue oxidative damage was lower than in rats given saline.
Peptide
Elamipretide (SS-31)
Outcome
DecreaseMyocardial lipid peroxidation
Study
ratn = 16
Myocardial ischemia-reperfusion by LAD ligation
Comparator
Saline
Outcome group
Oxidative stress · Cardiovascular
Studied dose
3 mg/kg · intraperitoneal · Two doses: 30 min before ligation and 5 min before reperfusionAs given in this study (rat).
Source sentences
Summary
Lipid peroxidation was significantly reduced by both SS-31 and SS-20 treatment.
2 context sentences(design, population, supporting numbers)
Summary · context
Rats (n=8/group) were randomized to SS-31, SS-20 or placebo.
Summary · context
The drugs (3 mg/kg) or saline was administered intraperitoneally 30 min before ligation of the left anterior descending artery for 60 min, and another dose given intraperitoneally 5 min before reperfusion for 60 min.
Report a problemFND-1742929603

Studies that did not test the peptide alone2

In this study, Elamipretide (SS-31) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Elamipretide (SS-31).

04AnimalNot a test of Elamipretide (SS-31) aloneAnimal study (in vivo)Efficacy outcome
In rats with ischemia-reperfusion, arrhythmia was less frequent in the peptide treatment groups, including SS‑31, than in controls.
In plain wordsIn rats given SS‑31 before a heart attack, abnormal heart rhythms were less frequent than in rats given saline.
Peptide
Elamipretide (SS-31)
Outcome
DecreaseArrhythmia frequency
Study
ratn = 16
Myocardial ischemia-reperfusion by LAD ligation
Comparator
Saline
Outcome group
Cardiovascular events · Cardiovascular
Source sentences
Summary
Arrhythmia occurred only during the early period of coronary occlusion and was less frequent and less severe in the peptide treatment groups than in the controls (Lambeth score 5 points, 3 points, versus 13 points in the controls, P<0.05).
2 context sentences(design, population, supporting numbers)
Summary · context
Rats (n=8/group) were randomized to SS-31, SS-20 or placebo.
Summary · context
The drugs (3 mg/kg) or saline was administered intraperitoneally 30 min before ligation of the left anterior descending artery for 60 min, and another dose given intraperitoneally 5 min before reperfusion for 60 min.
In this study, Elamipretide (SS-31) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Elamipretide (SS-31).
Report a problemFND-1742929604
05AnimalNot a test of Elamipretide (SS-31) aloneAnimal study (in vivo)Efficacy outcome
In rats with ischemia-reperfusion, arrhythmia was less severe in the peptide treatment groups, including SS‑31, than in controls.
In plain wordsIn rats given SS‑31 before a heart attack, abnormal heart rhythms were less severe than in rats given saline.
Peptide
Elamipretide (SS-31)
Outcome
DecreaseArrhythmia severity (Lambeth score)
Study
ratn = 16
Myocardial ischemia-reperfusion by LAD ligation
Comparator
Saline
Outcome group
Cardiovascular events · Cardiovascular
Measurements
Lambeth score
13 points
Control
Source sentences
Summary
Arrhythmia occurred only during the early period of coronary occlusion and was less frequent and less severe in the peptide treatment groups than in the controls (Lambeth score 5 points, 3 points, versus 13 points in the controls, P<0.05).
2 context sentences(design, population, supporting numbers)
Summary · context
Rats (n=8/group) were randomized to SS-31, SS-20 or placebo.
Summary · context
The drugs (3 mg/kg) or saline was administered intraperitoneally 30 min before ligation of the left anterior descending artery for 60 min, and another dose given intraperitoneally 5 min before reperfusion for 60 min.
In this study, Elamipretide (SS-31) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Elamipretide (SS-31).
Report a problemFND-1742929605

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
9 Oct 2026, 18:17 UTC
Study results updated
Version 1
9 Oct 2026, 02:47 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.